Introduction to Afrezza and Its Role in Diabetes Management

Afrezza (insulin human) inhalation powder represents a significant departure from traditional injectable insulin therapy. Approved by the U.S. Food and Drug Administration in 2014 for both type 1 and type 2 diabetes, this rapid-acting inhaled insulin offers a needle-free alternative that may improve adherence and quality of life for many patients. However, as with any novel therapeutic approach, understanding its long-term effectiveness in maintaining blood glucose control is essential for clinicians and patients making informed decisions about diabetes management.

Diabetes affects approximately 537 million adults worldwide, and achieving glycemic targets remains a persistent challenge despite advances in insulin formulations and delivery systems. Injectable insulin, while highly effective, can be a barrier to optimal therapy due to injection anxiety, pain, and the inconvenience of multiple daily injections. Afrezza addresses these issues by delivering insulin via a small, breath-activated inhaler, providing rapid absorption through the lungs. This pharmacokinetic profile allows Afrezza to mimic the natural prandial insulin response more closely than many rapid-acting injectable analogs, potentially reducing postprandial hyperglycemia and improving overall glycemic control when used consistently over many years.

The purpose of this article is to critically assess the long-term effectiveness of Afrezza based on available clinical trial data, real-world evidence, and safety considerations. We will explore how sustained use of Afrezza impacts HbA1c levels, hypoglycemia rates, and patient-reported outcomes, while also addressing practical challenges such as pulmonary safety, cost, and accessibility.

Mechanism of Action and Pharmacokinetics

Afrezza consists of dry-powder insulin formulated into Technosphere microparticles. When inhaled, these particles rapidly dissolve in the lung’s neutral pH environment, releasing monomeric insulin that is quickly absorbed into the systemic circulation. Peak insulin concentrations are reached within 12–15 minutes of inhalation, compared to 30–90 minutes for rapid-acting injectable analogs like insulin lispro or aspart. This ultrafast onset enables administration immediately before meals, closely matching the natural insulin surge that occurs with eating.

The duration of action for Afrezza is typically 2–3 hours, which is shorter than that of injectable rapid-acting insulins. This abbreviated profile may reduce the risk of late postprandial hypoglycemia and basal insulin stacking when used in combination with long-acting basal insulin regimens. In patients with type 2 diabetes, Afrezza can be used as monotherapy or as an adjunct to oral agents, providing flexibility in treatment planning.

Importantly, the pulmonary route of insulin delivery bypasses the subcutaneous depot, leading to more predictable absorption and less inter- and intra-patient variability. This consistency is a key advantage for long-term blood sugar stability, as it reduces the guesswork in dosing and timing that often complicates injectable insulin therapy.

Long-Term Effectiveness: Evidence from Clinical Trials

The cornerstone of assessing Afrezza’s long-term effectiveness lies in randomized controlled trials (RCTs) that followed patients for six months to two years. The pivotal Phase III studies, such as the Affinity 1 (Type 1) and Affinity 2 (Type 2) trials, provided initial evidence of glycemic benefits. In these studies, patients using Afrezza in combination with basal insulin achieved HbA1c reductions of 0.4–0.8% from baseline, comparable to those seen with rapid-acting injectable comparators. Notably, Afrezza-treated patients reported significantly lower rates of severe hypoglycemia and nocturnal hypoglycemia, a finding that has been replicated in subsequent analyses.

HbA1c Improvement Over Extended Periods

Longer-term data from open-label extension studies have shown that the glycemic improvements observed in the first six months are generally maintained for up to two years with continued Afrezza use. In a pooled analysis of 1,200 patients, the mean HbA1c remained stable at approximately 0.4% below baseline after 24 months, suggesting that tolerance to the insulin effect does not develop and that adherence does not wane substantially over time. However, these studies are limited by a high dropout rate, often due to patient preference, coughing, or insufficient glycemic control, which may introduce selection bias.

Hypoglycemia and Glycemic Variability

A major attraction of Afrezza is its potential to reduce hypoglycemia, particularly severe hypoglycemia requiring assistance. In a meta-analysis of eight RCTs, the relative risk of severe hypoglycemia with Afrezza was 0.65 compared with injectable rapid-acting insulins. This safety advantage is thought to derive from the ultra-rapid absorption and short duration of action, which minimize the window for prolonged hypoglycemic effect. Additionally, continuous glucose monitoring (CGM) data from a 12-week study showed that time in range (TIR) was comparable between Afrezza and insulin lispro, with a trend toward less time below range (<70 mg/dL) in the Afrezza group.

For patients who experience frequent or unpredictable hypoglycemia with injectable insulin, the switch to Afrezza may offer a meaningful improvement in long-term safety and quality of life.

Real-World Evidence and Comparative Effectiveness

While clinical trials provide controlled data, real-world evidence (RWE) offers insights into how Afrezza performs in routine clinical practice over extended periods. Several retrospective analyses of insurance claims databases and electronic health records have examined persistence, adherence, and outcomes in patients using Afrezza for up to three years.

Adherence and Persistence Rates

One of the purported benefits of inhaled insulin is improved adherence due to the elimination of injections. A real-world analysis of 1,500 patients initiating Afrezza found that the 12-month persistence rate (proportion continuing therapy) was approximately 55%, which is comparable to, but not superior to, persistence rates for injectable rapid-acting insulins. However, among patients who persisted, the average medication possession ratio (MPR) was high (>80%), suggesting good adherence once the regimen was established. The most common reasons for discontinuation were inadequate glycemic control, cost, and cough.

Comparative Effectiveness in Type 2 Diabetes

In type 2 diabetes patients inadequately controlled on oral agents, Afrezza has been compared with non-insulin injectables such as GLP-1 receptor agonists. A propensity-matched cohort study found that patients initiating Afrezza experienced a mean HbA1c reduction of 0.7% at six months, compared with 0.6% for those starting liraglutide. While the difference was not statistically significant, Afrezza users had a higher frequency of hypoglycemia (mostly mild) and a higher discontinuation rate related to respiratory symptoms. For some patients who prioritize a rapid onset of action and flexibility, Afrezza may be an appropriate alternative, but its long-term comparative value depends on individual tolerance and cost considerations.

Safety Profile Over Long-Term Use

The most significant concern with inhaled insulin is the potential for pulmonary adverse effects over years of repeated administration. Because Afrezza deposits insulin into the alveolar epithelium, questions have been raised about local inflammation, changes in lung function, and the risk of interstitial lung disease.

Pulmonary Function Changes

Clinical trials monitored forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing capacity of the lungs for carbon monoxide (DLCO) at regular intervals. Results showed a small, non-progressive decline in FEV1 (approximately 40 mL/year) compared with injectable comparators, which was statistically significant but not clinically meaningful in most patients. The decline plateaued after 6–12 months and did not accelerate with continued use for up to two years. However, patients with pre-existing lung disease (e.g., asthma, COPD) were excluded from these trials, so long-term safety in these populations remains unknown.

A post-marketing safety surveillance program required by the FDA has not identified a signal for severe pulmonary toxicity, such as pulmonary fibrosis, as of 2024. Nonetheless, the FDA recommends periodic spirometry testing (e.g., at baseline and every 6–12 months) for all Afrezza users to detect any individual changes early. Patients who experience a decline of more than 20% in FEV1 should discontinue therapy.

Cough and Respiratory Symptoms

Cough is the most common adverse event, reported in approximately 10–15% of patients in trials, often occurring immediately after inhalation. Most coughs are mild to moderate and resolve with continued use, but persistent cough may lead to discontinuation. Less common events include throat irritation, bronchitis, and dysphonia. Patients should be counseled about these potential side effects and instructed on proper inhaler technique to minimize cough (e.g., deep, rapid inhalation followed by a breath hold).

Benefits That Support Long-Term Use

Despite the challenges, Afrezza offers unique advantages that may justify its long-term use in selected patients.

  • Rapid onset and short duration: Allows precise meal-time dosing, reducing the need for pre-meal timing and minimizing late hypoglycemia. Many patients report greater lifestyle flexibility.
  • Non-invasive delivery: Particularly appealing for patients with needle phobia or those who require multiple daily injections, potentially improving psychological well-being and treatment satisfaction.
  • Portability and convenience: The small, discreet inhaler eliminates the need for syringes, pens, or refrigeration, making it easier to administer insulin in social or work settings.
  • Reduced nocturnal hypoglycemia: The rapid clearance of Afrezza lowers the risk of severe hypoglycemic events during sleep, a major concern for many patients using long-acting insulin combinations.
  • Potential weight neutrality: Unlike some injectable insulins that may promote weight gain, clinical data suggest Afrezza is weight-neutral over long-term use, which is advantageous for patients with type 2 diabetes struggling with weight management.

Challenges That Impact Long-Term Effectiveness

No therapy is without drawbacks, and Afrezza has several factors that can limit its sustained use.

Glycemic Control Gaps

Because Afrezza has a short duration of action, patients must also use long-acting basal insulin (in type 1 diabetes) or oral agents with extended coverage. Inadequate basal coverage can lead to hyperglycemia between meals and overnight. The need for two separate insulin preparations—one inhaled, one injected—may paradoxically increase treatment complexity in some cases.

Cost and Insurance Coverage

Afrezza is significantly more expensive than generic injectable rapid-acting insulins. Without insurance coverage, the monthly cost can exceed $500, making it inaccessible for many patients. Even with some insurance plans, prior authorization requirements and high copayments can deter long-term adherence. Cost is the most frequently cited reason for discontinuation in real-world studies.

Limited Dosing Range

Afrezza is available in 4-, 8-, and 12-unit single-dose cartridges. Patients requiring larger doses (e.g., >24 units per meal) must use multiple inhalations, which can be cumbersome and increase the risk of dosing errors. The lack of a higher-dose cartridge restricts use for patients with severe insulin resistance.

Pulmonary Safety Monitoring

Mandatory lung function testing adds a layer of provider burden and may be a barrier for patients with limited access to spirometry. Some patients may be reluctant to undergo repeated testing, leading to lapses in monitoring and potential unapproved continuation in the presence of lung function decline.

Patient Selection and Clinical Considerations

To optimize long-term outcomes with Afrezza, careful patient selection is paramount. Ideal candidates include adults with type 1 or type 2 diabetes who are motivated to use a non-injectable alternative, have normal pulmonary function, and can afford or have insurance coverage for the medication. Patients with a history of asthma, COPD, or smoking should be evaluated individually, though current labeling contraindicates Afrezza in those with chronic lung disease.

Monitoring and Follow-Up

Long-term management requires regular assessment of both glycemic outcomes and pulmonary health. The American Diabetes Association (ADA) recommends that patients on Afrezza have spirometry at baseline and annually thereafter. More frequent testing may be warranted if symptoms occur. HbA1c and self-monitored blood glucose or CGM data should be reviewed every 3–6 months, with adjustments in meal-time and basal insulin as needed.

Practical Tips for Adherence

Healthcare providers can support long-term adherence by addressing common barriers. Providing detailed instructions on inhaler use, discussing cost-saving options like manufacturer coupons or patient assistance programs, and setting realistic expectations about cough and dosing convenience can improve persistence. Scheduling a follow-up visit 2–4 weeks after initiation allows early intervention for any issues.

Future Directions and Ongoing Research

The long-term effectiveness of Afrezza will continue to be refined by ongoing studies. A large pragmatic trial sponsored by the manufacturer is evaluating cardiovascular safety over a follow-up of 3–5 years, as cardiovascular outcomes remain a key endpoint for all glucose-lowering therapies. Additionally, newer formulations with improved particle engineering may further reduce cough and enhance lung deposition. Researchers are also exploring the use of Afrezza in closed-loop artificial pancreas systems, where the ultra-rapid pharmacokinetics could improve algorithm performance.

For now, Afrezza stands as a validated option for selected patients who prioritize needle-free delivery and are willing to commit to pulmonary monitoring. When used consistently, it can deliver comparable glycemic control to injectable rapid-acting insulins with a favorable hypoglycemia profile.

Conclusion

Assessing the long-term effectiveness of Afrezza in blood sugar control requires a balanced view of its benefits, risks, and practical limitations. Clinical trials and real-world data confirm that sustained use can achieve meaningful HbA1c reductions with a lower risk of severe hypoglycemia compared to traditional injectable insulins. The rapid onset of action aligns well with lifestyle demands, and for many patients, the non-invasive route of administration improves treatment satisfaction and adherence.

However, challenges such as pulmonary safety monitoring, higher cost, dosing limitations, and the inability to use as a standalone insulin in type 1 diabetes mean that Afrezza is not a universal replacement for injectable insulin. Its long-term effectiveness is highly dependent on appropriate patient selection, diligent follow-up, and financial accessibility. Clinicians should engage in shared decision-making with patients, weighing the unique trade-offs of Afrezza against individual preferences and clinical needs.

As more post-marketing data accumulate, the evidence base for Afrezza’s long-term effectiveness will strengthen. For now, it remains a valuable tool in the diabetes armamentarium, particularly for those seeking to minimize injections without compromising glycemic outcomes. Ongoing vigilance regarding pulmonary safety will ensure that this novel delivery system can be used safely for years to come.